Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tedizolid - Merck & Co

Drug Profile

Tedizolid - Merck & Co

Alternative Names: BAY 1192631; DA-70157; DA-70218; DA-7157; DA-7218; MK-1986; SIVEXTRO; Sivextro; Tedizolid phosphate; Torezolid; Torezolid phosphate; TR-700; TR-701; TR-701 FA; TR-701 free acid

Latest Information Update: 21 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST; Merck & Co
  • Class Antibacterials; Oxazolidinones; Skin disorder therapies; Small molecules
  • Mechanism of Action Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase III Nosocomial pneumonia
  • Phase I Gram-positive infections
  • No development reported Bacteraemia

Most Recent Events

  • 15 Feb 2019 Phase-I clinical trials in Gram-positive infections (In infants, In neonates) in USA, Bulgaria, Norway (PO), (IV) (NCT03217565) (EudraCT2017-000953-38)
  • 02 Jan 2019 Phase-III clinical trials in Skin and soft tissue infections (In children, In infants) in USA (PO) (NCT03176134)
  • 21 Dec 2018 Merck Sharp & Dohme Corp. completes a phase I trial in Gram-positive infections (In children) in United Kingdom, Ukraine, Norway, Colombia and USA (PO, Suspension and IV, Infusion) (NCT02750761)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top